Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Fresh Phase 2 data in cutaneous sarcoidosis (CS) show results strong enough to justify a Phase 3 launch later this year, pending FDA consultation marking yet another de-risking step for what is shaping up to be a potential blockbuster asset
As we approach this transition, we know you may have many questions about availability, substitutions, cost, insurance coverage, and more
Koreans don't even care that much, she said
are shareholders of ImmuPharma PLC, the parent company of UREKA Sarl
Patients are responsible for paying a $99 onboarding fee and any copayments, but there's no monthly subscription fee
10.1001/jama.2018.0220 82 MacInnisM
US$ 24.43
US$ 20.78
US$ 26.69
US$ 21.60
US$ 22.46
US$ 25.90
